Condition: Skin Cancer Melanoma · Sponsor: Nuvana Healthcare LTD
This study evaluates the feasibility and accuracy of an AI-powered mobile platform (NuvanaDx) for early detection of skin cancer, including melanoma, using smartphone-based imaging. The platform is designed to improve access to early diagnosis, reduce waiting times, and support triage into appropriate care pathways.
This description comes directly from the study's public registry record.
Sushma Saxena, Director, Nuvana Healthcare Ltd · +44 7481986525 · sushma.saxena@nuvana.co.uk
Always discuss trial participation with your own doctor first.
| Nuvana Healthcare Ltd | London, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07144306